Where it is used and how it works?Tetrabenazineis used...
Favipiravir is an influenza drug which was approvedfor clinical use in Japan in the year 2014.
Influenza attacks your respiratory system.Sometimes, its complications can be deadly. But for most people, influenzaresolves on its own. Flu viruses travel through the air in droplets whensomeone with the infection sneezes, coughs, or talks.
Medical authorities in China have said a drug in Japan to treat new strains of influenza appeared to be effective in coronavirus patients. The officials said that the drug has a high degree of safety and is clearly effective in treatment.
At this time, there are studies that Favipiravir has the capability to treat people with the infection of coronavirus. Coronavirus is a large family of viruses that may cause illness in humans or animals. Several coronaviruses reasons for respiratory infections which ranges from the common cold to more severe illnesses. These diseases include Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). COVID-19 is the most recent discovered coronavirus disease. This infection is spread from person to person. It may be through small droplets from the one who is infected through sneezing or coughing. Some people don’t develop any symptoms or don’t feel any unwell and get infected. After exposure to the virus, the appearance of the symptoms may take up to 14 days. Symptoms of the disease may be very mild or more serious such as:
As the news goes by, doctors in Japan are usingFavipiravir in clinical studies on coronavirus patients with mild yo moderatesymptoms. Hoping that it will also prevent the virus from multiplying inpatients. But, there is a source in Japan said that the drug was not aseffective in people with more severe symptoms. Favipiravir would still needgovernment approval for full-scale use on COVID-19 patients. Because it wasoriginally intended to treat flu.
The mechanism of action of this drug is novelcompared to existing influenza antivirals that primarily prevent entry and exitof the virus from cells. The active RNA polymerase inhibits and preventsreplication of the viral genome. Some studies have shown that when Favipiraviris incorporated into an RNA strand, it prevents RNA strand elongation and viralproliferation.
A recent study was a non-randomized comparison oftwo treatment regimens across time. On their study in day one,the group comprises 35 people and gave 1,600 mg of Favipiravir twice inseparate doses plus inhaled interferon. On day two, the group reduced theirdosage to 600 mg twice each day and kept taking inhaled interferon. Patientswho took Favipiravir cleared the virus in an average of 4 days. The researcherswho conducted this study have shown significant improvement in chest imagingcompared with the control arm. The statistical calculations have also shownthat Favipiravir was independently associated with faster viral clearance.Through this non-randomized study, it showed significantly better treatmenteffects on COVID-19 in terms of disease progression and